Central Nervous System Lymphoma, Gastric Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Splenic Mantle Cell Lymphoma
Conditions
Brief summary
This phase I/II trial studies the side effects and the best dose of v-akt murine thymoma viral oncogene homolog (Akt)/mitogen-activated protein kinase 1(ERK) inhibitor ONC201 and to see how well it works in treating patients with non-Hodgkin's lymphoma that has returned after a period of improvement or does not respond to treatment. Akt/ERK inhibitor ONC201 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Detailed description
PRIMARY OBJECTIVES: I. To determine recommended phase II dose for oral ONC201 (Akt/ERK inhibitor ONC201) in patients with relapsed/refractory lymphomas. (Phase I) II. To identify toxicities associated with oral ONC201 in patients with relapsed/refractory lymphomas. (Phase I) III. To determine the objective response rate to ONC201 in patients with relapsed/refractory lymphomas. (Phase II) SECONDARY OBJECTIVES: I. To determine the pharmacokinetics (PK) of oral ONC201 following administration. (Phase I) II. To observe the anti-tumor effects of oral ONC201, if any occur, in patients with relapsed/refractory lymphomas. (Phase I) III. Confirm tolerability of recommended phase II dose. (Phase II) IV. Assess clinical outcomes associated with ONC201 treatment in patients with relapsed/refractory lymphomas. (Phase II) V. Correlate clinical outcome with tumor and serum biomarkers. (Phase II) OUTLINE: This is a phase I, dose-escalation study followed by a phase II study. Patients receive Akt/ERK inhibitor ONC201 orally (PO) on day 1 of every cycle or day 1 of every week. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months.
Interventions
Given PO
OTHERLaboratory Biomarker Analysis
Correlative studies
OTHERPharmacological Study
Correlative studies
Sponsors
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Phase 1 and Phase 2: confirmed diagnosis of previously treated relapsed and/or refractory lymphoma; patients with central nervous system (CNS) lymphoma are included * Patient with leukemia phase (peripheral blood involvement), CNS lymphoma \[including cerebrospinal fluid (CSF)-only disease\], non-measurable disease, gastrointestinal (GI) mantle cell lymphoma (MCL), or bone marrow (BM) MCL are also eligible; gastrointestinal or bone marrow or spleen only patients are allowable and will be analyzed separately * All adverse events related to prior therapies (chemotherapy, radiotherapy, and/or surgery) must be resolved to =\< grade 1, except for alopecia * Patients must be willing to receive transfusions of blood products * Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less * Serum creatinine \< 2.0 mg/dl * Serum bilirubin \< 1.5 mg/dl * Platelet count \> 50,000/mm\^3 * Absolute neutrophil count (ANC) \> 1,000/mm\^3 * Alanine aminotransferase (ALT), or aspartate aminotransferase (AST) \< 2 x upper limit of normal or \< 5 x upper limit of normal if hepatic metastases are present * Willing and able to participate in all study related procedures and therapy including swallowing capsules without difficulty * Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test and must be willing to use acceptable methods of birth control during the study and for 90 days after the last dose of study treatment; acceptable methods of birth control include condoms with birth control foam, birth control pills, implantable or injectable birth control, birth control patch, intrauterine device (IUD), or diaphragm with spermicidal gel; male patients must use an effective barrier method of contraception (i.e. , condoms with birth control foam or diaphragm with spermicidal gel) during the study and for 90 days following the last dose of study treatment if sexually active with a female of childbearing potential; contraception must be in place at least 2 weeks prior to initiating study treatment; a female of childbearing potential is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) * Patient must be English-speaking \[MD Anderson Symptom Inventory (MDASI) completion only\]
Exclusion criteria
* Any serious medical condition including but not limited to, uncontrolled hypertension, uncontrolled diabetes mellitus, uncontrolled infection, active/symptomatic coronary artery disease, chronic obstructive pulmonary disease (COPD), renal failure, active hemorrhage, or psychiatric illness that, in the investigators opinion places the patient at unacceptable risk or would prevent the subject from signing the informed consent form * Pregnant or breast feeding females * Use of any standard/experimental anti-lymphoma drug therapy, including steroids (dexamethasone dose \>= 4 mg/day or prednisone \>= 20 mg/day), within 3 weeks of initiation of the study or use of any experimental non-drug therapy (e.g., donor leukocyte/mononuclear cell infusions) within 56 days of initiation of the study drug treatment; hydroxyurea is permitted up to 24 hours before the first dose of study drug in patients with rapidly-proliferating disease * Prior allogeneic stem cell transplant (SCT) within 16 weeks or autologous SCT within 8 weeks of initiation of therapy (patients that require immunosuppressive therapy are not eligible within 60 days of therapy) * History of human immunodeficiency virus (HIV) infection; patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody); hepatitis C infection is allowed as long as there is no active disease and is cleared by GI consultation; HIV screening is not required for this study * Significant neuropathy (grades 3-4, or grade 2 with pain) within 14 days prior to enrollment * Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction, or any other gastrointestinal condition that could interfere with the absorption and metabolism of ONC201 * Major surgery within 4 weeks of initiation of therapy * The patient has a prior or concurrent malignancy that in the opinion of the investigator, presents a greater risk to the patient's health and survival, than of the MCL, within the subsequent 6 months at the time of consent; investigator discretion is allowed * Patients with New York Heart Association (NYHA) class III and IV heart failure, myocardial infarction in the preceding 6 months, and significant conduction abnormalities, including but not limited to second (2nd) degree atrioventricular (AV) block type II, third (3rd) degree block, QT prolongation (corrected QT \[QTc\] \> 500 msec), sick sinus syndrome, ventricular tachycardia, symptomatic bradycardia (heart rate \< 50 beats per minute \[bpm\]), hypotension, light headedness and syncope; patients with active atrial fibrillation will be excluded; the protocol excludes patients who have within the past year had a stent and by recommendation of their cardiologist need to stay on anticoagulants such as warfarin equivalent vitamin K antagonist * History of allergic reactions attributed to compounds of similar chemical or biologic composition to ONC201 or its excipients * Acute infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to initiation of study * Active alcoholism or use of recreational drug (evaluated by history taking)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recommended Phase 2 Dose (RP2D) (Phase I) | 21 days | — |
| Number of Participants With Overall Response Rate (Phase 1 and 2) | Up to 63 days (first 3 courses) | Defined as either progressive disease or stable disease observed assessed by the Revised International Workshop Standardization Response Criteria for non-Hodgkin lymphoma. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | every 3 months for 1 year, then every 6 months, up to 3 years | Overall survival is the time in months from start of study treatment to date of death due to any cause. |
| Progression-free Survival (PFS)- (Phase 2) | every 3 months for 1 year, then every 6 months, up to 6 years | Progression free survival is defined as time in weeks from start of study treatment to first documentation of objective tumor progression or up to death due to any cause, whichever occurs first. |
Countries
United States
Participant flow
Recruitment details
Patients recruited at MD Anderson Lymphoma clinic from November 2015 through April 2018
Pre-assignment details
A total of 16 participants consented for the protocol, 11 participated on the study, 4 of the participants were screen failures and 1 withdrew consent.
Participants by arm
| Arm | Count |
|---|---|
| ONC201 125 mg Patients receive Akt/ERK inhibitor ONC201 125 mg PO on day 1 of every cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. | 4 |
| ONC201 250 mg Patients receive Akt/ERK inhibitor ONC201 250 mg PO every 7 days. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. | 2 |
| ONC201 625 mg Patients receive Akt/ERK inhibitor ONC201 625 mg PO every 7 days. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. | 5 |
| Total | 11 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Adverse Event | 1 | 0 | 0 |
| Overall Study | Death | 0 | 0 | 1 |
| Overall Study | Progressive disease | 2 | 2 | 4 |
| Overall Study | Withdrawal by Subject | 1 | 0 | 0 |
Baseline characteristics
| Characteristic | ONC201 125 mg | ONC201 250 mg | ONC201 625 mg | Total |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 3 Participants | 2 Participants | 4 Participants | 9 Participants |
| Age, Categorical Between 18 and 65 years | 1 Participants | 0 Participants | 1 Participants | 2 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 3 Participants | 2 Participants | 4 Participants | 9 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 4 Participants | 2 Participants | 5 Participants | 11 Participants |
| Region of Enrollment United States | 4 participants | 2 participants | 5 participants | 11 participants |
| Sex: Female, Male Female | 1 Participants | 0 Participants | 2 Participants | 3 Participants |
| Sex: Female, Male Male | 3 Participants | 2 Participants | 3 Participants | 8 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 4 | 0 / 2 | 1 / 5 |
| other Total, other adverse events | 4 / 4 | 2 / 2 | 5 / 5 |
| serious Total, serious adverse events | 0 / 4 | 1 / 2 | 1 / 5 |
Outcome results
Primary
Number of Participants With Overall Response Rate (Phase 1 and 2)
Defined as either progressive disease or stable disease observed assessed by the Revised International Workshop Standardization Response Criteria for non-Hodgkin lymphoma.
Time frame: Up to 63 days (first 3 courses)
Population: 1 patient passed away prior to restaging in Phase 2 Arm B
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| ONC201 125 mg | Number of Participants With Overall Response Rate (Phase 1 and 2) | Progressive Disease | 3 Participants |
| ONC201 125 mg | Number of Participants With Overall Response Rate (Phase 1 and 2) | Stable Disease | 1 Participants |
| ONC201 250 mg | Number of Participants With Overall Response Rate (Phase 1 and 2) | Progressive Disease | 1 Participants |
| ONC201 250 mg | Number of Participants With Overall Response Rate (Phase 1 and 2) | Stable Disease | 1 Participants |
| ONC201 625 mg | Number of Participants With Overall Response Rate (Phase 1 and 2) | Progressive Disease | 3 Participants |
| ONC201 625 mg | Number of Participants With Overall Response Rate (Phase 1 and 2) | Stable Disease | 1 Participants |
Primary
Recommended Phase 2 Dose (RP2D) (Phase I)
Time frame: 21 days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ONC201 125 mg | Recommended Phase 2 Dose (RP2D) (Phase I) | 125 mg |
Secondary
Overall Survival (OS)
Overall survival is the time in months from start of study treatment to date of death due to any cause.
Time frame: every 3 months for 1 year, then every 6 months, up to 3 years
Population: Overall survival for each arm measured in months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ONC201 125 mg | Overall Survival (OS) | 29 months |
| ONC201 250 mg | Overall Survival (OS) | 15 months |
| ONC201 625 mg | Overall Survival (OS) | 24 months |
Secondary
Progression-free Survival (PFS)- (Phase 2)
Progression free survival is defined as time in weeks from start of study treatment to first documentation of objective tumor progression or up to death due to any cause, whichever occurs first.
Time frame: every 3 months for 1 year, then every 6 months, up to 6 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ONC201 125 mg | Progression-free Survival (PFS)- (Phase 2) | 5 weeks |